Share on StockTwits

GenMark Diagnostics (NASDAQ:GNMK) SVP Jon Faiz Kayyem sold 50,000 shares of the stock on the open market in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $14.05, for a total value of $702,500.00. Following the transaction, the senior vice president now directly owns 106,155 shares of the company’s stock, valued at approximately $1,491,478. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Needham & Company initiated coverage on shares of GenMark Diagnostics in a research note to investors on Thursday, December 19th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Raymond James cut their price target on shares of GenMark Diagnostics from $15.00 to $14.00 in a research note to investors on Wednesday, November 13th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. GenMark Diagnostics currently has an average rating of “Buy” and an average target price of $14.80.

Shares of GenMark Diagnostics (NASDAQ:GNMK) traded down 0.85% on Friday, hitting $13.93. The stock had a trading volume of 178,421 shares. GenMark Diagnostics has a 1-year low of $8.75 and a 1-year high of $16.00. The stock has a 50-day moving average of $12.54 and a 200-day moving average of $11.62. The company’s market cap is $577.8 million.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.27) by $0.03. The company had revenue of $4.64 million for the quarter, compared to the consensus estimate of $4.60 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. Analysts expect that GenMark Diagnostics will post $-0.90 EPS for the current fiscal year.

GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.